|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SNHG21 |
Gene summary for SNHG21 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SNHG21 | Gene ID | 100505616 |
| Gene name | small nucleolar RNA host gene 21 | |
| Gene Alias | FSD2-AS1 | |
| Cytomap | 15q25.2 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 100505616 | SNHG21 | LZE4T | Human | Esophagus | ESCC | 3.78e-08 | 2.01e-01 | 0.0811 |
| 100505616 | SNHG21 | LZE7T | Human | Esophagus | ESCC | 1.62e-04 | 2.20e-01 | 0.0667 |
| 100505616 | SNHG21 | LZE8T | Human | Esophagus | ESCC | 1.10e-02 | 1.33e-01 | 0.067 |
| 100505616 | SNHG21 | LZE20T | Human | Esophagus | ESCC | 4.98e-02 | 9.64e-02 | 0.0662 |
| 100505616 | SNHG21 | LZE24T | Human | Esophagus | ESCC | 2.65e-05 | 1.52e-01 | 0.0596 |
| 100505616 | SNHG21 | P1T-E | Human | Esophagus | ESCC | 7.11e-04 | 2.48e-01 | 0.0875 |
| 100505616 | SNHG21 | P2T-E | Human | Esophagus | ESCC | 8.84e-05 | 8.93e-02 | 0.1177 |
| 100505616 | SNHG21 | P4T-E | Human | Esophagus | ESCC | 4.59e-20 | 4.53e-01 | 0.1323 |
| 100505616 | SNHG21 | P8T-E | Human | Esophagus | ESCC | 1.97e-10 | 1.81e-01 | 0.0889 |
| 100505616 | SNHG21 | P9T-E | Human | Esophagus | ESCC | 2.38e-11 | 2.73e-01 | 0.1131 |
| 100505616 | SNHG21 | P10T-E | Human | Esophagus | ESCC | 4.05e-32 | 5.34e-01 | 0.116 |
| 100505616 | SNHG21 | P12T-E | Human | Esophagus | ESCC | 4.30e-10 | 2.22e-01 | 0.1122 |
| 100505616 | SNHG21 | P15T-E | Human | Esophagus | ESCC | 1.35e-04 | 1.17e-01 | 0.1149 |
| 100505616 | SNHG21 | P16T-E | Human | Esophagus | ESCC | 1.30e-15 | 3.63e-01 | 0.1153 |
| 100505616 | SNHG21 | P20T-E | Human | Esophagus | ESCC | 9.54e-15 | 2.91e-01 | 0.1124 |
| 100505616 | SNHG21 | P21T-E | Human | Esophagus | ESCC | 1.12e-04 | 1.79e-01 | 0.1617 |
| 100505616 | SNHG21 | P22T-E | Human | Esophagus | ESCC | 2.13e-27 | 4.80e-01 | 0.1236 |
| 100505616 | SNHG21 | P23T-E | Human | Esophagus | ESCC | 5.94e-18 | 3.77e-01 | 0.108 |
| 100505616 | SNHG21 | P24T-E | Human | Esophagus | ESCC | 8.40e-04 | 8.08e-02 | 0.1287 |
| 100505616 | SNHG21 | P26T-E | Human | Esophagus | ESCC | 1.47e-14 | 2.36e-01 | 0.1276 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |